Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting.
De novo
mCRPC
mCSPC, survival
mHSPC
metastatic prostate cancer
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
revised:
22
05
2024
received:
11
04
2024
accepted:
25
05
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
The landscape of systemic therapies for metastatic hormone-sensitive (mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the last decades resulting in a significantly prolonged overall survival. However, subgroup analyses of phase III trials suggest potentially different overall survival outcomes for older adults. We relied on our institutional metastatic prostate cancer database to identify mHSPC and subsequently mCRPC patients. Older adults were stratified according to age groups 70-74 versus ≥75-79 versus ≥80 years at metastatic occurrence. Subsequently, uni- and multivariable time to mCRPC and overall survival analyses were performed. Of 494 older adults, 217 (44%) were 70-74 versus 180 (36%) 75-79 versus 97 (20%) ≥80 years old. Rates of local prostate cancer treatment differed significantly between all three groups (p < 0.01). Regarding mHSPC treatment, androgen receptor signaling inhibitors (ARSI) were administered in 30-39% of patients and docetaxel with 9% in age group 70-74 years and 6% and 3% in age groups 75-79 years and ≥80 years. Regarding mCRPC treatment, significant differences between treatment proportions were observed (p < 0.01). Most common treatment was ARSI for all three groups. Conversely, chemotherapy was more frequently administered in patients aged 70-74 (16%), relative to 4% and 3% in 75-79 year and ≥80 year aged patients. In univariable and multivariable time to mCRPC analyses, overall survival in mHSPC and OS in mCRPC analyses, no significant differences between all three age groups were observed (all p ≥ 0.3). Treatment patterns differ significantly between older adults with metastatic prostate cancer. However, these differences may not result in differences of overall life expectancy.
Sections du résumé
BACKGROUND
BACKGROUND
The landscape of systemic therapies for metastatic hormone-sensitive (mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the last decades resulting in a significantly prolonged overall survival. However, subgroup analyses of phase III trials suggest potentially different overall survival outcomes for older adults.
METHODS
METHODS
We relied on our institutional metastatic prostate cancer database to identify mHSPC and subsequently mCRPC patients. Older adults were stratified according to age groups 70-74 versus ≥75-79 versus ≥80 years at metastatic occurrence. Subsequently, uni- and multivariable time to mCRPC and overall survival analyses were performed.
RESULTS
RESULTS
Of 494 older adults, 217 (44%) were 70-74 versus 180 (36%) 75-79 versus 97 (20%) ≥80 years old. Rates of local prostate cancer treatment differed significantly between all three groups (p < 0.01). Regarding mHSPC treatment, androgen receptor signaling inhibitors (ARSI) were administered in 30-39% of patients and docetaxel with 9% in age group 70-74 years and 6% and 3% in age groups 75-79 years and ≥80 years. Regarding mCRPC treatment, significant differences between treatment proportions were observed (p < 0.01). Most common treatment was ARSI for all three groups. Conversely, chemotherapy was more frequently administered in patients aged 70-74 (16%), relative to 4% and 3% in 75-79 year and ≥80 year aged patients. In univariable and multivariable time to mCRPC analyses, overall survival in mHSPC and OS in mCRPC analyses, no significant differences between all three age groups were observed (all p ≥ 0.3).
CONCLUSIONS
CONCLUSIONS
Treatment patterns differ significantly between older adults with metastatic prostate cancer. However, these differences may not result in differences of overall life expectancy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
Références
Mandel P, Hoeh B, Wenzel M, et al. Triplet or doublet therapy in metastatic hormone‐sensitive prostate cancer patients: a systematic review and network meta‐analysis. Eur Urol Focus. Published online September 1. 2022;9(1):96‐105. S2405‐4569(22)00176‐6. doi:10.1016/j.euf.2022.08.007
Preisser F, Chun FelixK H, Banek S, et al. Management and treatment options for patients with de novo and recurrent hormone‐sensitive oligometastatic prostate cancer. Prostate Int. Published Online January 18. 2021;9:113‐118. doi:10.1016/j.prnil.2020.12.003
Hoeh B, Garcia CC, Wenzel M, et al. Triplet or doublet therapy in metastatic hormone‐sensitive prostate cancer: updated network meta‐analysis stratified by disease volume. Eur Urol Focus. Published online April 11. 2023;9(5):838‐842. S2405‐4569(23)00094‐9. doi:10.1016/j.euf.2023.03.024
Wenzel M, Preisser F, Hoeh B, et al. Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies. Front Oncol. 2021;11:659135. doi:10.3389/fonc.2021.659135
Wenzel M, Garcia CC, Hoeh B, et al. Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy. Prostate. 2023;83(14):1365‐1372. doi:10.1002/pros.24599
Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone‐sensitive prostate cancer: long‐term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol off J Am Soc Clin Oncol. 2018;36(11):1080‐1087. doi:10.1200/JCO.2017.75.3657
Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone‐sensitive prostate cancer. N Engl J Med. 2022;386(12):1132‐1142. doi:10.1056/NEJMoa2119115
Wenzel M, Würnschimmel C, Nocera L, et al. Overall survival after systemic treatment in high‐volume versus low‐volume metastatic hormone‐sensitive prostate cancer: systematic review and network meta‐analysis. Eur Urol Focus. Published online April 11. 2021;8(2):399‐408. S2405‐4569(21)00109‐7. doi:10.1016/j.euf.2021.04.003
Darolutamide Plus Androgen‐Deprivation Therapy and Docetaxel in Metastatic Hormone‐Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial—PubMed. Accessed July 28, 2023. https://pubmed.ncbi.nlm.nih.gov/36795843/
Hoyle AP, Ali A, James ND, et al. Abiraterone in “high‐” and “low‐risk” metastatic hormone‐sensitive prostate cancer. Eur Urol. 2019;76(6):719‐728. doi:10.1016/j.eururo.2019.08.006
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration‐sensitive prostate cancer (PEACE‐1): a multicentre, open‐label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet Lond Engl. 2022;399(10336):1695‐1707. doi:10.1016/S0140‐6736(22)00367‐1
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for Oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650‐659. doi:10.1001/jamaoncol.2020.0147
Mourey L, Boyle HJ, Roubaud G, et al. Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/− docetaxel in older patients (≥70 years), with de novo metastatic‐castration sensitive prostate cancer, compared to younger patients (<70 years): the PEACE‐1 trial. J Clin Oncol. 2023;41(6_suppl):20‐20. doi:10.1200/JCO.2023.41.6_suppl.20
Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first‐line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121‐131. doi:10.1056/NEJMoa1903835
Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration‐sensitive prostate cancer. N Engl J Med. 2019;381(1):13‐24. doi:10.1056/NEJMoa1903307
Wenzel M, Collà Ruvolo C, Würnschimmel C, et al. Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. Prostate. 2022;82(1):78‐85. doi:10.1002/pros.24249
Fernando M, Anton A, Weickhardt A, et al. Treatment patterns and outcomes in older adults with castration‐resistant prostate cancer: analysis of an Australian real‐world cohort. J Geriatr Oncol. 2023;14(8):101621. doi:10.1016/j.jgo.2023.101621
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration‐sensitive prostate cancer. N Engl J Med. 2017;377(4):352‐360. doi:10.1056/NEJMoa1704174
Kessler ER. Management of Metastatic Prostate Cancer in frail/elderly patients. Oncol Williston Park N. 2018;32(11):570‐573.
Droz JP, Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int. 2008;101(Suppl 2):23‐29. doi:10.1111/j.1464‐410X.2007.07486.x
Wenzel M, Würnschimmel C, Chierigo F, et al. Pattern of biopsy Gleason grade group 5 (4 + 5 vs 5 + 4 vs 5 + 5) predicts survival after radical prostatectomy or external beam radiation therapy. Eur Urol Focus. 2022;8(3):710‐717. doi:10.1016/j.euf.2021.04.011
Wenzel M, Würnschimmel C, Ruvolo CC, et al. Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores. Prostate. 2021;81(12):874‐881. doi:10.1002/pros.24184
Stolzenbach LF, Deuker M, Collà‐Ruvolo C, et al. External beam radiation therapy improves survival in low‐volume metastatic prostate cancer patients: a North American population‐based study. Prostate Cancer Prostatic Dis. Published online September 1. 2021;24(1):253‐260. doi:10.1038/s41391‐020‐00276‐2
Shayegan B, Wallis CJD, Hamilton RJ, et al. Real‐world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population‐based cohort study in Canada. Prostate Cancer Prostatic Dis. 2023;26(1):74‐79. doi:10.1038/s41391‐022‐00514‐9
Marchioni M, Di Nicola M, Primiceri G, et al. New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta‐analysis. J Urol. 2020;203(4):751‐759. doi:10.1097/JU.0000000000000636
Bencina G, Petrova E, Sönmez D, Matos Pereira S, Dimitriadis I, Salomonsson S. HTA and reimbursement status of metastatic hormone‐sensitive prostate cancer, non‐metastatic castration‐resistant prostate cancer, and metastatic castration‐resistant prostate cancer treatments in Europe: a patient access landscape review. J Health Econ Outcomes Res. 2023;10(1):102‐110. doi:10.36469/001c.75208
Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real‐world treatment patterns and overall survival among men with metastatic castration‐resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. Published Online October 2. 2023;27(2):327‐333. doi:10.1038/s41391‐023‐00725‐8
Hoeh B, Würnschimmel C, Flammia RS, et al. Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. Prostate. 2021;81(16):1374‐1381. doi:10.1002/pros.24235
Guo X, Xia H, Zhang F, Hao G. Real‐world progression in the survival of de novo metastatic prostate cancer over the past decade. Urol Oncol. Published online December 13. 2024;42(3):68.e1‐68.e9. S1078‐1439(23)00419‐2. doi:10.1016/j.urolonc.2023.11.021
Würnschimmel C, Wenzel M, Wang N, et al. Long‐term overall survival of radical prostatectomy patients is often superior to the general population: a comparison using life‐table data. Prostate. 2021;81(11):785‐793. doi:10.1002/pros.24176
Sinibaldi VJ. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging. 2007;2(4):555‐560. doi:10.2147/cia.s1395